Healthcare Mergers, Acquisitions & Ventures Week

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Healthcare Mergers, Acquisitions & Ventures Week

Learn More

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Buy Now



Biotechnology Business



Reports summarize biotechnology business study results from Amgen, Inc.



May 17th, 2008

According to recent research published in the Journal of Neuroscience Methods, "The discovery of novel analgesic Compounds that target some receptors can be challenging due to species differences in ligand pharmacology. If a putative analgesic compound has markedly lower affinity for rodent versus other mammalian orthologs of a receptor, the evaluation of antinociceptive efficacy in non-rodent species becomes necessary."

"Here, we describe a new, efficient method for measuring inflammation-associated nociception in conscious rabbits. An electronic von Frey device is used, consisting of a rigid plastic tip connected to a force transducer in a hand-held probe. The...


Source: Healthcare Mergers, Acquisitions & Ventures Week (2008-05-17)